XENE Xenon Pharmaceuticals Inc
XNAS 36.60 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
XENE
$36.60
—
Key stats
$36.60
- 52-Week Range
- $33.38 – $72.66
- YTD
- -17.72%
- IV Rank (30D)
- 35.79
- Straddle Price
- $4.67
- P/C Vol Ratio
- 2.02
- Market Cap
- $3.5B
- Open
- $35.92
- Day Range
- $35.70 – $36.90
- Volume
- 176,193
- Prev Close
- $35.95
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.77 |
| Cost of Equity (CAPM) | 9.02% (VRP-adj) |
| WACC | 9.02% |
| Volatility Risk Premium | -28.6pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.3B |
| Return on Equity (TTM) | -32.9% |
| Book / Price | 40.0% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $49.04 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $36.28 |
| Bollinger Width / SMA20 | 42.9% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $3B |
Peers used for multiples: ACAD, ALKS, BIIB, DNTH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
59%
20-Day Fair Value
≈ by Nov 20, 2026
$37.02
α +1.2%
rank 68%
conviction
70%
40-Day Fair Value
≈ by Dec 21, 2026
$37.17
α +1.6%
rank 68%
conviction
52%
60-Day Fair Value
≈ by Jan 19, 2027
$37.20
α +1.7%
rank 61%
conviction
59%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 43.0× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 33.8× · 3 peers |
| Peer P/B | $46.47 | 13% | median 3.2× · 4 peers |
| Peer P/S | n/a | 0% | median 4.0× · 4 peers |
| Market Anchor (SMA50) | $49.04 | 55% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | $36.16 | 32% | 21 strikes · skew -0.28 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $3.5B
- Employees
- 370
- List Date
- 2014-11-05
- CIK
- 0001582313
- Next Earnings
- 2026-11-02 (After-Close)
- EPS Forecast
- ($1.17) (8 est.)
- Headquarters
- Burnaby
- Homepage
- https://www.xenon-pharma.com
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -2.65% | -14.15% | 4.91% | 0.69% | -0.47% | -7.82% | -3.25% |
| Feb | 20.13% | 6.95% | 0.71% | 1.66% | -6.40% | 4.29% | 4.56% |
| Mar | -0.11% | -3.75% | -11.30% | -8.09% | -6.26% | 36.66% | 1.19% |
| Apr | -3.02% | -12.64% | 9.78% | -3.54% | 24.67% | -1.15% | 2.35% |
| May | -0.86% | -9.29% | -3.63% | -10.40% | -24.26% | -2.49% | -8.49% |
| Jun | 0.59% | 14.02% | -0.39% | 1.43% | 4.09% | 13.01% | 5.46% |
| Jul | -6.65% | 7.66% | -3.48% | 14.43% | -4.83% | 3.98% | 1.85% |
| Aug | 0.40% | 22.51% | 4.28% | -7.75% | 26.92% | -3.28% | 7.18% |
| Sep | -15.81% | -8.68% | -14.02% | -1.94% | 2.16% | -38.02% | -12.72% |
| Oct | 99.68% | 1.47% | -6.23% | 1.81% | 7.16% | -6.06%* | 16.31% |
| Nov | -19.84% | -0.65% | 17.17% | 2.25% | 8.75% | -- | 1.54% |
| Dec | 20.94% | 6.77% | 25.16% | -6.93% | 3.01% | -- | 9.79% |
| Total | 72.57% | 3.52% | 17.53% | -17.29% | 27.15% | -16.20% | 14.55% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $36.20
SMA 50: $48.46
SMA 200: $52.52
Current: $36.58
EMA 12: $36.08
EMA 26: $39.57
MACD: -3.4862 | Signal: 0.9284
BEARISH
ADX (14): 47.63
STRONG TREND
+DI: 17.66
−DI: 34.74
Momentum Oscillators
RSI (14): 37.19
NEUTRAL
Stoch %K: 51.72
Stoch %D: 38.02
Williams %R: -33.95
Volume & Volatility
BB Upper: $38.91
BB Lower: $33.49
NEUTRAL
OBV: -8,370,637
Vol SMA 20: 1,777,923
Vol ROC: -92.34%
ATR: $1.66
True Range: $1.20
HV 20: 38.6%
HV 30: 112.6%
HV 60: 82.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Positive news sentiment from recent headlines
- Strong technical momentum signals, including a bullish MACD crossover
- Moderate volatility with a beta of 0.89 relative to the market
Primary Risks:
- Overbought RSI reading at 76.95, potentially indicating a near-term pullback
- Recent insider sales could be seen as negative news sentiment
Investment Thesis: XENE is poised for continued upside momentum, driven by positive news headlines and strong technical signals. The stock's moderate volatility and beta relative to the market suggest that it can continue to outperform in the short term.
Recent News Sentiment Impact: The recent news headlines have been overwhelmingly positive, with a sentiment score of 3/5. This has likely contributed to the stock's upward momentum over the past few months.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Uptrend; Medium-term (1-3 months): Uptrend; Long-term (3-12 months): Uptrend
Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- SMA 20: $58.59
- SMA 50: $56.20
- SMA 200: $48.12
- EMA 12: $63.23
- EMA 26: $59.53
Momentum Signals:
- RSI interpretation: Overbought at 76.95, potentially indicating a near-term pullback.
- MACD signal: Bullish crossover with a reading of 3.71 / Signal: 1.45 / Histogram: 2.26 (bullish).
- Bollinger Bands position: Neutral, with the price touching the upper band.
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 1974392.25
- On-Balance Volume (OBV): 27801089.97
- Volume Rate of Change: 37.62%
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- Positive news headlines related to metastatic prostate cancer market growth and Phase 3 study results.
- Neutral headline about insider sales, which could be seen as a negative signal.
Sentiment Assessment: Aggregate news sentiment: POSITIVE (4/5)
Catalyst Identification: Upcoming events, earnings, product launches, regulatory changes:
- No upcoming earnings or product launch dates available.
- Regulatory catalysts may include FDA approvals for PARP inhibitors and PSMA-targeted radioligand therapies.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market (beta >1.2 = high risk, <0.8 = defensive):
- Beta: 0.89 (vs SPY) - moderate volatility.
Volatility Regime: Current vs historical volatility levels:
- Stock volatility: 0.61
- Historical volatility: HV20 43.6% / HV30 42.6% / HV60 36.6%
Options Market Signals: IV rank, put/call ratios, unusual activity:
- IV Rank: 16.1% (Low) - shows if volatility is historically high/low.
- Current IV: 67.4%
- Expected Move: $11.60 (42 DTE), 7-DTE: $6.85
- Volume Flow: 879 calls vs 170 puts
- Open Interest: 382 calls vs 120 puts
- Put/Call Volume Ratio: 0.19 (Bullish sentiment)
- Put/Call OI Ratio: 0.31
Downside Protection: Support levels and risk management considerations:
- SMA 20: $58.59 - potential support level.
- SMA 50: $56.20 - potential support level.
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- Sector: Biotechnology (high relative strength).
- Market: S&P 500 (moderate relative strength).
Institutional Activity: Volume patterns suggesting institutional interest signals:
- Moderate institutional interest, with a volume flow of 879 calls vs 170 puts.
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- Correlation: 0.19 - moderate correlation.
- R-squared value: N/A.
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- SMA 20: $58.59
- SMA 50: $56.20
- Upper Bollinger Band: $70.42
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- SMA 200: $48.12 (potential support level).
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- No upcoming earnings or product launch dates available.
Risk Management: Stop-loss levels and position sizing considerations:
- Set a stop-loss order at the SMA 20 ($58.59) to limit potential losses.
- Consider scaling into the position with a 50% allocation.
This report aims to provide an objective analysis of XENE's technical, fundamental, and news-driven performance. The stock's recent upward momentum is driven by positive news headlines and strong technical signals. However, the overbought RSI reading at 76.95 suggests that the stock may be due for a near-term pullback. As such, it is essential to consider risk management strategies and adjust positions accordingly.
Generated
News
All XENE news →
Earnings History
20 of 22 under expected move
Avg Expected Move
12.44%
Avg Actual Move
4.85%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-01 | After-Close | 19.42% | 12.83% | 0.66x | Within |
| 2021-05-11 | After-Close | 5.30% | 2.79% | 0.53x | Within |
| 2021-08-11 | After-Close | 19.27% | 4.39% | 0.23x | Within |
| 2021-11-10 | After-Close | 13.08% | 6.21% | 0.47x | Within |
| 2022-03-01 | After-Close | 8.78% | 3.09% | 0.35x | Within |
| 2022-05-10 | After-Close | 16.73% | 5.71% | 0.34x | Within |
| 2022-08-09 | After-Close | 15.76% | 0.84% | 0.05x | Within |
| 2022-11-08 | After-Close | 5.37% | 6.61% | 1.23x | Exceeded |
| 2023-03-01 | After-Close | 11.43% | 7.39% | 0.65x | Within |
| 2023-05-09 | After-Close | 9.26% | 5.51% | 0.60x | Within |
| 2023-11-08 | After-Close | 10.42% | 6.69% | 0.64x | Within |
| 2024-02-29 | After-Close | 8.69% | 0.76% | 0.09x | Within |
| 2024-05-09 | After-Close | 9.48% | 4.59% | 0.48x | Within |
| 2024-08-08 | After-Close | 13.90% | 3.19% | 0.23x | Within |
| 2024-11-12 | Pre-Market | 7.77% | 1.54% | 0.20x | Within |
| 2025-02-27 | After-Close | 11.49% | 3.37% | 0.29x | Within |
| 2025-05-12 | After-Close | 13.04% | 17.43% | 1.34x | Exceeded |
| 2025-08-11 | After-Close | 8.80% | 5.51% | 0.63x | Within |
| 2025-11-03 | Pre-Market | 10.97% | 1.91% | 0.17x | Within |
| 2026-02-26 | After-Close | 35.17% | 3.76% | 0.11x | Within |
| 2026-05-07 | After-Close | 8.93% | 0.79% | 0.09x | Within |
| 2026-08-06 | After-Close | 10.57% | 1.84% | 0.17x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
XENE Options Activity & IV Rank
XENE IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 52.6%
7-DTE IV: —
Expected Move: $4.67
7-DTE Move: $4.67
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 161
Put Volume: 325
P/C Volume: 2.019
BEARISH
Call OI: 2,319
Put OI: 370
P/C OI: 0.16
Total OI: 2,689
ATM Options Pricing
ATM Call: $1.70
ATM Put: $2.98
Call %: 4.6%
Put %: 8.1%
Chain Summary
Chain Volume: 1,841
Chain OI: 11,611
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 76th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
76%
vs own history
GEX tilt
+0.87
OI-weighted, today
Vanna tilt
+0.90
δ-sensitivity to IV
Charm tilt
-0.88
δ-decay vs time
Vanna tilt +0.90: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.88: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 20 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
28%
+8.2
pts
EXTREME
ATM 54.8% / Wing 63.0%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)35.8MediumOct 22
Straddle Price (30 DTE)$4.67Oct 22
Beta Analysis
Risk Metrics
Beta: 0.8064
Alpha: -4.74%
Correlation: 0.1511
R-Squared: 2.3%
Stock Volatility: 68.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own XENE
6 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $84.6M | #470 of 6285 | -47.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $22.7M | #1050 of 3716 | +86.7% | 13F | |
| Duquesne Family Office Family office Stanley Druckenmiller | $14.4M | #59 of 86 | 0.0% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $11.3M | #992 of 3138 | -37.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $7.9M | #838 of 1945 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $12K | #3937 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
XENE Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 86,364,312 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$62.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $43.94M | 70.23% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $11.44M | 18.28% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $2.32M | 3.70% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $1.67M | 2.66% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $1.44M | 2.31% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $1.20M | 1.92% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $335.92K | 0.54% | 2025-09-30 |
| 8 | Simplex Trading, LLC Custodian | $223.33K | 0.36% | 2026-06-30 |
7 filers$7.91M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $4.38M | 55.31% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $1.19M | 15.03% | 2026-06-30 |
| 3 | Wolverine Trading, LLC Custodian | $898.38K | 11.35% | 2025-09-30 |
| 4 | IMC-Chicago, LLC Custodian | $597.56K | 7.55% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $513.06K | 6.48% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $259.55K | 3.28% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $78.47K | 0.99% | 2026-06-30 |
XENE Insider Trading (Form 4)
Latest: 2026-10-16Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Thomas Patrick Kelly | Chief Financial Officer | Exer (M) | +7,500 | — | EDGAR | |
| 2026-10-01 | Thomas Patrick Kelly | Chief Financial Officer | Buy (P) | +15,000 | $37.32 | $559.7K | EDGAR |
| 2026-10-01 | Ian Mortimer | PRESIDENT & CEO | Buy (P) | +30,000 | $37.38 | $1.12M | EDGAR |
| 2026-09-03 | Dawn Svoronos | Director | Exer (M) | +5,144 | $8.15 | $41.9K | EDGAR |
| 2026-08-31 | Christopher John Kenney | Chief Medical Officer | Sell (S) | −7,068 | $60.25 | -$425.8K | EDGAR |
| 2026-08-13 | Steven Gannon | Director | Sell (S) | −10,000 | $64.06 | -$640.6K | EDGAR |
| 2026-06-08 | Gillian Cannon | Director | Sell (S) | −1,190 | $53.14 | -$63.2K | EDGAR |
| 2026-06-08 | Gary Patou | Director | Sell (S) | −1,322 | $53.14 | -$70.3K | EDGAR |
| 2026-06-03 | Steven Gannon | Director | Mixed | +1,229 | $53.41 | -$75.6K | EDGAR |
| 2026-06-03 | Patrick Machado | Director | Exer (M) | +2,645 | — | EDGAR | |
| 2026-06-03 | Elizabeth A. Garofalo | Director | Exer (M) | +2,645 | — | EDGAR | |
| 2026-06-03 | Gillian Cannon | Director | Exer (M) | +2,645 | — | EDGAR | |
| 2026-06-03 | Justin D. Gover | Director | Exer (M) | +2,645 | — | EDGAR | |
| 2026-06-03 | Dawn Svoronos | Director | Mixed | +1,229 | $53.41 | -$75.6K | EDGAR |
| 2026-06-03 | Gary Patou | Director | Exer (M) | +2,645 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
XENE Insider Holdings
12 insiders · @ $36.58
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ian Mortimer | PRESIDENT & CEO | 64,223 | $2.35M | -$23.63M | 26 | 2026-10-01 |
| 2 | Dawn Svoronos | Director | 31,373 | $1.15M | -$826.7K | 14 | 2026-09-03 |
| 3 | Gary Patou | Director | 29,798 | $1.09M | -$1.44M | 29 | 2026-06-08 |
| 4 | Thomas Patrick Kelly | Chief Financial Officer | 22,500 | $823.0K | $559.7K | 3 | 2026-10-16 |
| 5 | Andrea DiFabio | Chief Legal Officer | 8,643 | $316.2K | -$230.8K | 7 | 2026-03-13 |
| 6 | Sherry Aulin | Chief Financial Officer | 7,199 | $263.3K | -$1.38M | 6 | 2024-12-19 |
| 7 | Patrick Machado | Director | 2,645 | $96.8K | $0 | 7 | 2026-06-03 |
| 8 | Justin D. Gover | Director | 2,645 | $96.8K | $0 | 4 | 2026-06-03 |
| 9 | Elizabeth A. Garofalo | Director | 2,645 | $96.8K | -$95.6K | 7 | 2026-06-03 |
| 10 | Steven Gannon | Director | 1,870 | $68.4K | -$1.20M | 17 | 2026-08-13 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
XENE Board & Officers
As of SEC filings through Oct 16, 2026Directors 8
- Gary Patou · since Nov 4, 2014
- Steven Gannon · since May 21, 2015
- Dawn Svoronos · since Sep 27, 2016
- Patrick Machado · since Nov 5, 2020
- Elizabeth A. Garofalo · since Jun 3, 2021
- Ian Mortimer · listed since Jun 2021
- Gillian Cannon · since Aug 8, 2023
- Justin D. Gover · since Aug 8, 2023
Officers 5
- Ian Mortimer · President & CEO · listed since Jun 2021
- Thomas Patrick Kelly · Chief Financial Officer · since Oct 15, 2025
- Christopher John Kenney · Chief Medical Officer · since Aug 23, 2021
- Andrea DiFabio · Chief Legal Officer · since Nov 7, 2022
- Darren S Cline · Chief Commercial Officer · since Jun 23, 2025
Changes in the last 10 years (31)
| Oct 15, 2025 | Thomas Patrick Kelly became Chief Financial Officer |
| Jun 23, 2025 | Darren S Cline became Chief Commercial Officer |
| Feb 24, 2025 | The company announced the departure of Sherry Aulin as Chief Financial Officer in an SEC filing |
| Jan 17, 2025 | The company announced the departure of Christopher Von Seggern as Chief Commercial Officer in an SEC filing |
| Apr 15, 2024 | The company announced the departure of Simon N. Pimstone from the board in an SEC filing |
| Apr 15, 2024 | The company announced the departure of Simon N. Pimstone as Executive Chair in an SEC filing |
| Apr 15, 2024 | The company announced the departure of Mohammad Azab from the board in an SEC filing |
| Aug 8, 2023 | Justin D. Gover became a director |
| Aug 8, 2023 | Gillian Cannon became a director |
| Nov 7, 2022 | Andrea DiFabio became Chief Legal Officer |
| Mar 14, 2022 | Simon N. Pimstone first listed as Executive Chair in an SEC filing |
| Nov 16, 2021 | Simon N. Pimstone no longer listed as CEO in SEC filings |
| Aug 23, 2021 | Christopher John Kenney became Chief Medical Officer |
| Jun 3, 2021 | Sherry Aulin became Chief Financial Officer |
| Jun 3, 2021 | Ian Mortimer listed as President & CEO (previously President & CFO) in SEC filings |
| Jun 3, 2021 | Ian Mortimer first listed as a director in an SEC filing |
| Jun 3, 2021 | Elizabeth A. Garofalo became a director |
| Mar 15, 2021 | James R. Empfield listed as EVP, Drug Discovery (previously SVP, Drug Discovery) in SEC filings |
| Nov 5, 2020 | Patrick Machado became a director |
| Aug 17, 2020 | Christopher Von Seggern became Chief Commercial Officer |
| Jan 13, 2020 | Clarissa Desjardins became a director |
| Sep 18, 2019 | Ernesto Aycardi-Fonseca listed as CMO (previously Chief Medical Officer) in SEC filings |
| Sep 13, 2019 | Sherrington Robin listed as EVP, Strategy & Innovation (previously EVP Bus. & Corp. Development) in SEC filings |
| Mar 29, 2018 | Mark N Lampert reported in an SEC filing no longer being a 10% owner |
| Mar 29, 2018 | Bvf Partners L P/il reported in an SEC filing no longer being a 10% owner |
| Mar 29, 2018 | Bvf Inc/il reported in an SEC filing no longer being a 10% owner |
| Mar 19, 2018 | Ernesto Aycardi-Fonseca became Chief Medical Officer |
| Mar 13, 2018 | Simon N. Pimstone listed as CEO (previously President & CEO) in SEC filings |
| Mar 13, 2018 | Sherrington Robin listed as EVP Bus. & Corp. Development (previously SVP Bus. & Corp. Development) in SEC filings |
| Mar 13, 2018 | Ian Mortimer listed as President & CFO (previously CFO & COO) in SEC filings |
| Mar 14, 2017 | Y. Paul Goldberg listed as SVP, Clinical Development (previously VP of Clinical Development) in SEC filings |
Not reported recently (11)
- Sherrington Robin · Last reported as EVP, Strategy & Innovation in an SEC filing dated Mar 12, 2024
- James R. Empfield · Last reported as EVP, Drug Discovery in an SEC filing dated Mar 12, 2024
- Michael R Hayden · Last reported as a director in an SEC filing dated Jun 3, 2021
- Frank A Holler · Last reported as a director in an SEC filing dated Jun 1, 2021
- Michael M Tarnow · Last reported as a director in an SEC filing dated May 20, 2021
- Clarissa Desjardins · Last reported as a director in an SEC filing dated Jun 2, 2020
- Ernesto Aycardi-Fonseca · Last reported as CMO in an SEC filing dated Mar 13, 2020
- Richard H Scheller · Last reported as a director in an SEC filing dated Sep 18, 2019
- Charles J. Cohen · Last reported as VP, Biology in an SEC filing dated Dec 13, 2018
- Y. Paul Goldberg · Last reported as SVP, Clinical Development in an SEC filing dated Oct 24, 2017
- Raymond Winquist · Last reported as Head, Translational Research in an SEC filing dated Aug 21, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
XENE Proposed Insider Sales (Form 144)
Latest: 2026-08-28
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
2 filings
· $1.1M notice value
· 2 unique filers
· 50% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
STEVEN GANNON (1, $641K) · CHRISTOPHER KENNEY (1, $438K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-28 | CHRISTOPHER KENNEY | Officer | 7,068 | $437.7K | 2026-08-28 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-13 | STEVEN GANNON | Director | 10,000 | $640.6K | 2026-08-11 | RBC Wealth Management | — | EDGAR |
| 2026-06-05 | GILLIAN CANNON | Director | 1,190 | $63.1K | 2026-06-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-05 | GARY PATOU | Director | 1,322 | $70.1K | 2026-06-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-13 | CHRISTOPHER JOHN KENNEY | Officer | 1,410 | $77.9K | 2026-03-13 | Morgan Stanley Wealth Management… | 10b5-1 | EDGAR |
| 2026-03-13 | ANDREA DIFABIO | Officer | 1,342 | $74.1K | 2026-03-13 | Morgan Stanley Wealth Management… | 10b5-1 | EDGAR |
| 2026-03-13 | IAN MORTIMER | Officer, Director | 7,308 | $403.6K | 2026-03-13 | Morgan Stanley Wealth Management… | 10b5-1 | EDGAR |
| 2026-03-10 | ANDREA DIFABIO | Officer | 2,607 | $156.7K | 2026-03-10 | Morgan Stanley Wealth Management… | 10b5-1 | EDGAR |
| 2026-03-10 | CHRISTOPHER JOHN KENNEY | Officer | 2,771 | $166.6K | 2026-03-10 | Morgan Stanley Wealth Management… | 10b5-1 | EDGAR |
| 2026-03-10 | IAN MORTIMER | Officer, Director | 11,269 | $677.4K | 2026-03-10 | Morgan Stanley Wealth Management… | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
50 ETFs hold XENE
25 shown · $215.53M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.12% | $90.1M | $75.1B | 2026-10-20 |
| 2 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.24% | $32.8M | $13.6B | 2026-10-20 |
| 3 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.23% | $25.5M | $11.0B | 2026-10-20 |
| 4 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.12% | $21.2M | — | 2026-09-30 |
| 5 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.01% | $5.6M | $40.9B | 2026-10-20 |
| 6 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.08% | $5.2M | $6.6B | 2026-10-20 |
| 7 | NUSC Nuveen ESG Small-Cap ETF | Nport | 0.38% | $4.9M | — | 2026-07-31 |
| 8 | SBIO ALPS Medical Breakthroughs ETF | Nport | 2.90% | $4.7M | — | 2026-05-31 |
| 9 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.24% | $4.0M | — | 2026-09-30 |
| 10 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.13% | $3.4M | — | 2026-06-30 |
| 11 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $3.0M | — | 2026-09-30 |
| 12 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.11% | $3.0M | $2.7B | 2026-10-20 |
| 13 | FFSM Fidelity Fundamental Small-Mid Cap ETF | Nport | 0.12% | $1.8M | — | 2026-07-31 |
| 14 | RSSL Global X Russell 2000 ETF | Global X | 0.12% | $1.7M | — | 2026-10-21 |
| 15 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.04% | $1.5M | $3.8B | 2026-10-20 |
| 16 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.19% | $1.4M | — | 2026-05-31 |
| 17 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $988,902 | $20.6B | 2026-10-20 |
| 18 | SMMV iShares MSCI USA Small-Cap Min Vol Factor ETF | iShares (BlackRock) | 0.34% | $936,383 | $274.6M | 2026-10-20 |
| 19 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $881,107 | $10.9B | 2026-10-20 |
| 20 | ESGV Vanguard ESG U.S. Stock ETF | Vanguard | 0.01% | $773,603 | — | 2026-10-20 |
| 21 | FSML Franklin Small Cap Enhanced ETF | Franklin | 0.41% | $623,735 | $151.3M | 2026-10-20 |
| 22 | HRTS Tema Heart & Health ETF | Nport | 0.88% | $459,349 | — | 2026-05-31 |
| 23 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.81% | $373,889 | — | 2026-07-31 |
| 24 | FMED Fidelity Disruptive Medicine ETF | Fidelity | 0.65% | $336,078 | $51.7M | 2026-10-20 |
| 25 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $311,652 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-4.74
TTM Revenue
$0.00
TTM Net Income
$-409.19M
TTM Op. Cash Flow
$-337.52M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-110.74M | $-1.11 | $-95.39M |
| Q1 '26 | 2026-03-31 | — | $-102.30M | $-1.17 | $-88.90M |
| Q4 '25 | 2025-12-31 | $0.00 | $-105.26M | $-1.31 | $-81.48M |
| Q3 '25 | 2025-09-30 | — | $-90.90M | $-1.15 | $-71.75M |
| Q2 '25 | 2025-06-30 | — | $-84.71M | $-1.07 | $-64.23M |
| Q1 '25 | 2025-03-31 | $7.50M | $-65.05M | $-0.83 | $-61.65M |
| Q4 '24 | 2024-12-31 | — | $-65.69M | $-0.84 | $-54.38M |
| Q3 '24 | 2024-09-30 | — | $-62.79M | $-0.81 | $-49.66M |
| Q2 '24 | 2024-06-30 | — | $-57.92M | $-0.75 | $-31.15M |
| Q1 '24 | 2024-03-31 | — | $-47.93M | $-0.62 | $-46.19M |
| Q4 '23 | 2023-12-31 | — | $-44.74M | $-0.64 | $-35.40M |
| Q3 '23 | 2023-09-30 | — | $-48.46M | $-0.73 | $-48.08M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.54
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-32.9%
ROA
-31.6%
Div Yield
0.00%
FCF Yield
-10.69%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$3.16B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.04M
SI % of Float
6.66%
Days to Cover
1.58
Short Vol Ratio
66.4%
Free Float
90.76M
Float %
93.9%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-24